Over the last two decades, there have been tremendous advances in the non-invasive
diagnosis and risk stratification of chronic liver diseases (CLDs). Non-invasive approaches
are based on the quantification of biomarkers in serum samples or on the measurement of
liver stiffness, using either ultrasound-or magnetic resonance–based elastography
techniques. The fibrosis-4 index (non-patented) and enhanced liver fibrosis test (patented)
are the most widely adopted serum markers, whereas vibration-controlled transient …